HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shiseido Men Skin Care Launch Aims To Revive Sales

This article was originally published in The Rose Sheet

Executive Summary

Shiseido Men is positioned as a "highly functional" prestige skin care range that addresses everyday stressors, according to the Japanese beauty firm

You may also be interested in...



Shiseido acquires Joico

Japanese cosmetics firm is expanding U.S. professional business with acquisition of Joico Laboratories, a Los Angeles, Calif. salon hair care manufacturer, Shiseido announces Dec. 28. Joico will operate under Shiseido's wholly-owned professional subsidiary, Zotos International, the company said. Move marks Shiseido's fourth acquisition in the U.S. salon sector; firm purchased Zotos and Lamaur's professional products in 1988 and Helene Curtis Professional in 1996. Joico was founded by President and CEO Steve Stefano 25 years ago. Brands within the company's product portfolio include Joico, I.C.E. Hair, Vero and Triactive...

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel